GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Momentum Rank

ANTX (AN2 Therapeutics) Momentum Rank : 0 (As of Apr. 23, 2025)


View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Momentum Rank?

AN2 Therapeutics has the Momentum Rank of 0.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


AN2 Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


AN2 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Executives
Joshua M Eizen officer: See Remarks 3023 MONTBRETIA WAY, SAN RAMON CA 94582
Lucy Day officer: Chief Financial Officer 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Sanjay Chanda officer: Chief Development Officer C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Robin Shane Readnour director 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Eric Easom director, officer: Chief Executive Officer 171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund De, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Kabeer Aziz director 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Kevin Michael Krause officer: Chief Strategy Officer 369 27TH STREET, SAN FRANCISCO CA 94131
Margaret M Fitzpatrick director C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Melvin K Spigelman director THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Ra Capital Nexus Fund Ii, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak officer: Chief Accounting Officer 5941 OPTICAL COURT, SAN JOSE CA 95138

AN2 Therapeutics Headlines

From GuruFocus